News

Enlarge image

BusinessFranceSwitzerland

New cancer collaborations

30.01.2013 - Swiss 4-Antibody and Ludwig Institute will expand their cooperation, while Curie-Cancer and Genosplice Technology inked a cancer genomics pact.

The two new cancer collaborations were kicked-off yesterday. The French bioinformatics expert Genosplice Technology and the tech-transfer arm of Paris-based Institut Curie aim at developing high value-added cancer genomic approaches. GenoSplice will gain access to several Curie-Cancer technology platforms and research programmes and will contribute to the development of new products against cancer through genome mapping using its bioinformatics expertise. The partners aim to define a genomic map for prostate cancer including pathways and therapeutic options. In a second project the French will seek response biomarkers for a preclinical peptide that already has been proven effective in mouse xenograft experiments. 

On the same day, Swiss 4-Antibody AG and US-based Ludwig Institute expanded its existing cancer antibody development pact with three new targets provided by Brazilian antibody developer Recepta Biopharma SA. The partners will focus their R&D partnership on the generation of three antibodies targeting important cancer immune checkpoints. Under the terms of the agreement, 4-Antibody will use its high-throughput Retrocyte Display® technology platform to generate and produce fully human therapeutic antibody candidates. The Ludwig Institute will validate the new constructs and then, together with Recepta Biopharma, will take these antibody drugs into early clinical testing from 2015 in the US and Brazil.  

4-Antibody and Ludwig jointly will own the antibody drugs while Recepta Biopharma has baged exclusive commercial rights to Brazil in return for undisclosed licensing fees. 4-Antibody will take the lead securing commercialisation partners for the antibody drugs in territories outside Brazil on behalf of itself and Ludwig. Future returns from the collaboration outside of Brazil will be shared among the three parties.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-01/new-cancer-collaborations.html

R&DUKIreland

12.02.2016 The promise of the microbiome as the basis of new treatments has caught the attention of many. Now, UK biotherapeutics maker 4D pharma plc has padded its microbiome pipeline with the acquisition of Irish Tucana Health.

CommercialisationEU

10.02.2016 In future, meds will come in packages sporting a unique barcode and an anti-tampering device. These measures are part of the EU’s new regulation to safeguard against falsified medicines.

Clinical ResearchFrancePortugalEU

05.02.2016 It is not yet clear why a man died during a first-in-man clinical trial in January. A preliminary report found several “major shortcomings” by responsible CRO Biotrial. However, all regulations were complied with.

M&ASwitzerland

04.02.2016 After having dodged multiple takeover attempts by Monsanto last year, agrobusiness giant Syngenta has now agreed to be acquired by chemical corporation ChemChina. The Swiss company also announced plans to go public within a few years.

FinancingEUUKBelgium

01.02.2016 Newly formed Medicxi Ventures, a life sciences-dedicated VC firm based in London, Geneva and Jersey, has closed a €210m investment fund to reinvest in European early-stage assets.

ResearchUKEU

01.02.2016 Altering human DNA with the efficient gene editing method CRISPR/Cas9, especially germline modifications, was long considered a taboo. Now, however, UK scientists have received official approval to tinker with embryo DNA.

M&ASwedenIceland

28.01.2016 Swedish infectious disease specialist Enzymatica has bagged Icelandic company Zymetech, who produces the patent-protected enzyme used in Enzymatica’s own common cold blocker ColdZyme.

R&DUK

27.01.2016 Three UK universities have teamed up with three pharma companies to create the Apollo Therapeutics Fund. With the tech transfer fund, the consortium aims to develop scientific research into medicines.

Clinical TrialsGermany

25.01.2016 Affimed means to put a promising drug combination to the test. With support from MSD, the German biopharma will carry out clinical trials for an immunotherapy combining treatments of both companies.

AMREU

21.01.2016 Stop squandering antibiotics and make research profitable again: at the World Economic Forum in Swiss Davos, 83 pharmaceutical companies have called for a unified approach towards the threat of antimicrobial resistance.

Quick news provided by GlobeNewswire

View more stock news

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • PAION (D)1.77 EUR63.89%
  • 4SC (D)2.95 EUR11.32%
  • BIONOR PHARMA (N)0.86 NOK8.86%

FLOP

  • STENTYS (F)2.83 EUR-26.30%
  • BIOTIE THERAPEUTICS (FI)0.14 EUR-22.22%
  • KARO BIO (S)24.60 SEK-16.04%

TOP

  • VERONA PHARMA (UK)3.40 GBP25.9%
  • IXICO (UK)35.75 GBP21.2%
  • SERODUS (N)2.71 NOK15.8%

FLOP

  • BIONOR PHARMA (N)0.86 NOK-47.2%
  • STENTYS (F)2.83 EUR-44.3%
  • MOLMED (I)0.24 EUR-35.1%

TOP

  • CHRONTECH PHARMA (S)0.34 SEK3300.0%
  • KARO BIO (S)24.60 SEK3053.8%
  • 4SC (D)2.95 EUR243.0%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)8.65 SEK-86.0%
  • BIOTEST (D)13.79 EUR-85.3%
  • EVOCUTIS (UK)0.08 GBP-69.2%

No liability assumed, Date: 13.02.2016